Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Working Capital Change in Working Capital Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Shares Issued Shares Outstanding Shares Outstanding

Valion Bio (TIVC) Long-Term Debt Issuances (2021)

Valion Bio has reported Long-Term Debt Issuances over the past 1 years, most recently at -$2.5 million for Q4 2021.

For Q4 2021, Long-Term Debt Issuances changed N/A year-over-year to -$2.5 million; the TTM value through Dec 2021 reached -$1.7 million, changed N/A, while the annual FY2021 figure was $100000.0, N/A changed from the prior year.
Long-Term Debt Issuances for Q4 2021 was -$2.5 million at Valion Bio, down from $450000.0 in the prior quarter.
Over five years, Long-Term Debt Issuances peaked at $450000.0 in Q3 2021 and troughed at -$2.5 million in Q4 2021.